Profile data is unavailable for this security.
About the company
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
- Revenue in USD (TTM)79.60m
- Net income in USD-539.44m
- Incorporated2016
- Employees587.00
- LocationVir Biotechnology Inc1800 OWENS STREET, SUITE 900SAN FRANCISCO 94158United StatesUSA
- Phone+1 (415) 906-4324
- Fax+1 (302) 636-5454
- Websitehttps://www.vir.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MannKind Corp | 224.60m | 8.49m | 1.22bn | 414.00 | 192.06 | -- | 90.56 | 5.42 | 0.0234 | 0.0234 | 0.7589 | -0.8492 | 0.5766 | 2.69 | 11.34 | 542,509.70 | 2.18 | -26.07 | 2.84 | -37.80 | 70.99 | 59.68 | 3.78 | -57.61 | 3.57 | 1.50 | 1.80 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Xencor Inc | 162.18m | -133.36m | 1.26bn | 280.00 | -- | 2.05 | -- | 7.74 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.28bn | 20.00 | -- | 13.54 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 1.33bn | 171.00 | -- | 2.19 | -- | 65.09 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.35bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.37bn | 587.00 | -- | 0.8849 | -- | 17.23 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.38bn | 297.00 | 228.64 | 3.19 | 127.24 | 4.58 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| ANI Pharmaceuticals Inc | 517.46m | 30.57m | 1.39bn | 642.00 | 41.42 | 3.07 | 14.78 | 2.68 | 1.59 | 1.59 | 27.12 | 22.71 | 0.6161 | 1.77 | 2.98 | 806,012.40 | 4.23 | -2.83 | 5.02 | -3.35 | 62.71 | 60.18 | 6.87 | -6.15 | 3.12 | 3.67 | 0.3745 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Akero Therapeutics Inc | 0.00 | -179.27m | 1.40bn | 58.00 | -- | 1.66 | -- | -- | -3.20 | -3.20 | 0.00 | 12.24 | 0.00 | -- | -- | 0.00 | -28.43 | -37.73 | -29.53 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0395 | -- | -- | -- | -35.46 | -- | -- | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.42bn | 124.00 | -- | 2.14 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.43bn | 711.00 | 23.78 | 1.61 | 9.90 | 2.10 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Tarsus Pharmaceuticals Inc | 42.56m | -148.21m | 1.44bn | 244.00 | -- | 5.21 | -- | 33.72 | -4.72 | -4.72 | 1.35 | 7.29 | 0.1519 | -- | 2.63 | 174,430.30 | -52.88 | -31.56 | -58.73 | -33.82 | 92.37 | -- | -348.22 | -242.59 | 7.92 | -- | 0.0981 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Dynavax Technologies Corp | 236.15m | 9.22m | 1.44bn | 408.00 | 220.22 | 2.33 | 105.26 | 6.10 | 0.05 | 0.05 | 1.67 | 4.73 | 0.2414 | 0.7769 | 3.24 | 578,796.60 | 0.9427 | 4.16 | 1.02 | 5.71 | 80.34 | 64.83 | 3.91 | 9.19 | 14.10 | -- | 0.265 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.45bn | 174.00 | -- | 4.89 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Soleno Therapeutics Inc | 0.00 | -52.03m | 1.51bn | 33.00 | -- | 10.11 | -- | -- | -2.68 | -2.68 | 0.00 | 4.30 | 0.00 | -- | -- | 0.00 | -55.24 | -53.90 | -62.26 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.53bn | 120.00 | -- | 3.60 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Data as of May 15 2024. Currency figures normalised to Vir Biotechnology Inc's reporting currency: US Dollar USD
36.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 14.35m | 10.63% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 12.22m | 9.05% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.91m | 5.12% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 3.95m | 2.92% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.03m | 2.25% |
| AllianceBernstein LPas of 31 Dec 2023 | 2.78m | 2.06% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.89m | 1.40% |
| Bill & Melinda Gates Foundation Trust (Investment Management)as of 31 Dec 2023 | 1.56m | 1.16% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.39m | 1.03% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 1.34m | 1.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
